← Leaderboards
Graham S Timmins
$3,815,247
Attributed
$4,249,087
Total exposure
14
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $789.2K · FY2006–20$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$4,061,587 · 13
CDC$187,500 · 1
By mechanism
R21$1,891,119 · 5
R44$1,188,095 · 1
UH2$578,453 · 1
R41$205,299 · 1
R43$187,500 · 1
R03$150,000 · 1
Top collaborators
- Vojo P Deretic1 shared
- Jerrold J. Ellner1 shared
- Padmini Salgame1 shared
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoTuberculosisPharmaceutical PreparationsDrug ResistanceIn VitroStable IsotopeResistancePublic Health RelevanceClinical TrialsPre-ClinicalAnimal ModelInfectionMetabolismMycobacterium TuberculosisStagingReportingLabelDetectionMycobacterialBreath TestsProductionLungExhalationEnzymes
Grant awards (21)
Rifampin potentiation in NTM$205,299
R41 · FY2020 · AI · contact PI
Reversing Isoniazid Resistance By Isotopic Substitution$601,735
R44 · FY2018 · AI · contact PI
Overcoming Isoniazid Resistance in Tuberculosis with New Chemical Entitites$187,500
R43 · FY2018 · PS · contact PI
Reversing Isoniazid Resistance By Isotopic Substitution$586,360
R44 · FY2017 · AI · contact PI
Pyrazinamide Breath Test for TB$226,938
R21 · FY2016 · AI · contact PI
Autophagy-based HDT for tuberculosis$578,453
UH2 · FY2015 · AI
Pyrazinamide Breath Test for TB$188,750
R21 · FY2015 · AI · contact PI
Breath Test for Pseudomonas aeruginosa in CF$225,000
R21 · FY2010 · AI · contact PI
Nanostructured in vitro TB latency model$225,000
R21 · FY2010 · AI · contact PI
Breath Test for Pseudomonas aeruginosa in CF$187,500
R21 · FY2009 · AI · contact PI
Nanostructured in vitro TB latency model$187,500
R21 · FY2009 · AI · contact PI
Molecular Surrogate for Melanoma Prevention$75,000
R03 · FY2008 · CA · contact PI
Antimycobacterial NO from KatG Activation of Isoniazid$182,063
R21 · FY2007 · AI · contact PI
MOLECULAR IMAGING OF MELANOMA BY EPR$138,368
R21 · FY2007 · CA · contact PI
Molecular Surrogate for Melanoma Prevention$75,000
R03 · FY2007 · CA · contact PI
Antimycobacterial NO from KatG Activation of Isoniazid$187,500
R21 · FY2006 · AI · contact PI
MOLECULAR IMAGING OF MELANOMA BY EPR$142,500
R21 · FY2006 · CA · contact PI
USE OF EPR TO MEASURE INTRACELLULAR OXYGEN CONCENTRATION$18,233
P41 · FY2000 · RR
EPR OF OXYGEN PARTIAL PRESSURE DURING HYPOXIA, HYPEROXIA &BIOLUMINESCENCE$12,155
P41 · FY2000 · RR
USE OF SOLUBLE TRITYL SPIN PROBES FOR EPR OXIMETRY INVESTIGATIONS$12,155
P41 · FY2000 · RR
CONFIRMATION THAT ALA (5 AMINOLEVALINIC ACID) GENERATES HYDROXYL RADICAL IN VIVO$6,078
P41 · FY2000 · RR